PharmaView   Sep.2006

Pharmaceutical Marketers are facing increasing pressures: increasing competition; squeezed margins; shrinking budgets; more to do and less time to do it. It’s becoming difficult to work any harder, and of course it's always better to work smarter. Therefore we bring you the PharmaView.

PharmaView is a biweekly educational and informative newsletter for improving readers’ marketing knowledge and reporting the latest news in the pharma industry. It also provides great opportunities to exchange ideas, network and be recognized among your peers in the industry.

Through PharmaView, you can:

Learn peer’s experience in pharma marketing

Stay in touch with what’s happening in pharmaceutical marketing today

Be on the pioneering edge of pharmaceutical marketing

Have networking / idea exchange opportunities

About Us 

Integrating local knowledge with international perspective, Consultech Co. Ltd. offers its clients and prospects one-lstop solutions with sales and marketing consultancy, advertising and promotion strategies.

Asthma Treatment Approved by Health Canada for Relief of Symptoms of Seasonal Allergic Rhinitis Seasonal allergies can be troublesome for asthma sufferers

Sep 19, 2006

Novartis has received additional European Union approvals for Glivec® (imatinib)* to help patients with a rapidly progressive form of leukemia as well as a hard-to-treat solid cancer tumor. Both are rare and potentially life-lthreatening diseases with few, if any, approved treatments that have resulted in poor long-term outcomes.

Sep 19, 06

Lyrica's neuropathic pain indication broadened to include central nerve pain; Central nerve pain is associated with conditions such as spinal cord injury, stroke, and multiple sclerosis

Sep 18, 2006

GlaxoSmithKline Seeks U.S. Approval for Tykerb (lapatinib ditosylate) for the Treatment of Advanced Breast Cancer

GlaxoSmithKline plc today announced the submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for approval to market Tykerb (lapatinib ditosylate), in combination with Xeloda (capecitabine), for the treatment of advanced or metastatic HER2 (ErbB2) positive breast cancer in women who have received prior therapy,

Sept 18, 2006

Blueprint for the Brand

Implementing a strong brand-planning process is crucial to achieving standout in today's market.

Sep 19, 2006

The Science of DTC

Pharma once again has a spring in its step about consumer campaigns. Only this time, beaches and bold efficacy claims have been replaced by lab coats and risk information, as Merck and others data on how viewers absorb TV ads.

Sep 18, 2006

AstraZeneca says remains hungry for drug deals

AstraZeneca Plc is actively seeking more drug deals to fill its pipeline, despite a spree of acquisitions and licensing agreements over the past year, its head of development said on Tuesday.

Sept 19, 2006

Sanofi pasteur Broadens Pandemic Preparedness With First Clinical Trial of Novel Cell-Based H7N1 Vaccine

Sanofi pasteur, the vaccines business of the sanofi-aventis Group, has within the framework of FLUPAN, a collaborative research project funded by the European Commission, generated the first clinical trial lot of a new generation of H7N1 pandemic vaccine. This trial will broaden sanofi pasteur's pandemic preparedness program initiated with the development of H5N1 vaccines.

Sep 19, 2006

Peter Dolan Ousted

Bristol-Myers Squibb's board ousted Chief Executive Peter Dolan and General Counsel Richard Willard over their handling of negotiations with Apotex, a Canadian generic drugmaker. Shares jumped 2% to $23.87.

Sept 12, 2006

Please feel free to offer your opinions and advices about PharmaView in order to better our services. Should you have any comments, or if you want to unsubscribe  from PharmaView, please send us an email: pharmaview@Consultech.com.cn  . Thank you!